Emcure (EMCURE) | Financial Analysis & Statements
Emcure Pharmaceuticals Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
21.0B
Gross Profit
13.0B
61.82%
Operating Income
3.0B
14.49%
Net Income
2.1B
10.23%
EPS (Diluted)
₹10.92
Balance Sheet Metrics
Total Assets
82.3B
Total Liabilities
35.9B
Shareholders Equity
46.4B
Debt to Equity
0.77
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Emcure Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 78.1B | 66.6B | 59.3B | 57.7B | 49.9B |
| Cost of Goods Sold | 33.2B | 24.8B | 22.6B | 22.3B | 18.9B |
| Gross Profit | 44.9B | 41.8B | 36.7B | 35.3B | 31.0B |
| Gross Margin % | 57.5% | 62.8% | 61.9% | 61.3% | 62.2% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 8.4B | 7.7B | 6.4B | 5.7B | 4.9B |
| Other Operating Expenses | 8.1B | 16.6B | 7.6B | 7.0B | 5.3B |
| Total Operating Expenses | 16.5B | 24.3B | 14.0B | 12.7B | 10.2B |
| Operating Income | 10.8B | 9.2B | 9.4B | 10.9B | 9.7B |
| Operating Margin % | 13.9% | 13.8% | 15.9% | 18.9% | 19.4% |
| Non-Operating Items | |||||
| Interest Income | 90.4M | 207.6M | 118.3M | 102.0M | 69.9M |
| Interest Expense | 1.4B | 2.4B | 1.9B | 1.6B | 1.5B |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 9.7B | 7.3B | 7.5B | 9.7B | 8.4B |
| Income Tax | 2.6B | 2.0B | 1.9B | 2.7B | 2.3B |
| Effective Tax Rate % | 27.2% | 27.5% | 24.8% | 27.8% | 27.8% |
| Net Income | 7.1B | 5.3B | 5.6B | 7.0B | 4.2B |
| Net Margin % | 9.1% | 7.9% | 9.5% | 12.2% | 8.4% |
| Key Metrics | |||||
| EBITDA | 14.6B | 12.9B | 12.2B | 13.8B | 13.3B |
| EPS (Basic) | ₹36.43 | ₹27.57 | ₹29.43 | ₹36.63 | ₹21.69 |
| EPS (Diluted) | ₹36.43 | ₹27.57 | ₹29.43 | ₹36.63 | ₹21.69 |
| Basic Shares Outstanding | 180872608 | 180719481 | 180792757 | 180792757 | 180792757 |
| Diluted Shares Outstanding | 180872608 | 180719481 | 180792757 | 180792757 | 180792757 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Emcure Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.2B | 1.1B | 563.7M | 760.2M | 887.3M |
| Short-term Investments | 760.4M | 3.7B | 2.2B | 1.6B | 554.9M |
| Accounts Receivable | 20.0B | 18.6B | 16.5B | 13.1B | 14.8B |
| Inventory | 19.3B | 15.3B | 13.8B | 14.5B | 15.1B |
| Other Current Assets | 59.4M | 42.2M | 74.6M | 53.6M | 140.3M |
| Total Current Assets | 45.6B | 42.6B | 38.4B | 34.2B | 37.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.4B | 3.2B | 2.6B | 2.2B | 2.0B |
| Goodwill | 13.1B | 12.7B | 5.6B | 6.0B | 11.8B |
| Intangible Assets | 5.8B | 5.1B | 1.3B | 1.6B | 3.8B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 388.9M | - | 10.0K | - | - |
| Total Non-Current Assets | 36.8B | 35.5B | 28.4B | 26.4B | 30.9B |
| Total Assets | 82.3B | 78.1B | 66.7B | 60.6B | 68.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 14.8B | 13.1B | 10.9B | 11.3B | 9.7B |
| Short-term Debt | 5.8B | 13.5B | 14.7B | 13.9B | 16.5B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 158.1M | 153.2M | 84.1M | 12.1M | 90.2M |
| Total Current Liabilities | 26.7B | 32.1B | 30.2B | 29.6B | 34.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 4.5B | 9.8B | 8.6B | 8.3B | 8.2B |
| Deferred Tax Liabilities | 1.2B | 1.4B | 389.0M | 426.1M | 398.8M |
| Other Non-Current Liabilities | 144.9M | - | - | - | - |
| Total Non-Current Liabilities | 9.2B | 14.7B | 10.0B | 9.8B | 10.3B |
| Total Liabilities | 35.9B | 46.8B | 40.2B | 39.5B | 44.4B |
| Equity | |||||
| Common Stock | 1.9B | 1.8B | 1.8B | 1.8B | 1.8B |
| Retained Earnings | 33.1B | 26.3B | 22.0B | 17.0B | 17.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 46.4B | 31.2B | 26.5B | 21.1B | 23.7B |
| Key Metrics | |||||
| Total Debt | 10.2B | 23.3B | 23.3B | 22.2B | 24.7B |
| Working Capital | 18.9B | 10.5B | 8.2B | 4.6B | 3.1B |
Balance Sheet Composition
Emcure Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 9.7B | 7.3B | 7.5B | 9.7B | 6.6B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 19.9M | 39.7M | 52.8M | 57.2M | 63.5M |
| Working Capital Changes | -6.0B | -1.1B | -2.5B | -6.2B | -5.8B |
| Operating Cash Flow | 5.3B | 8.4B | 7.0B | 5.2B | 2.7B |
| Investing Activities | |||||
| Capital Expenditures | -1.9B | -2.4B | -3.9B | -3.8B | -1.1B |
| Acquisitions | 0 | -3.5B | 0 | -3.0B | -1.1B |
| Investment Purchases | -7.3B | -10.0B | -2.6B | -2.4B | -849.4M |
| Investment Sales | 9.9B | 8.9B | 1.9B | 1.4B | 702.2M |
| Investing Cash Flow | 680.2M | -7.0B | -4.6B | -7.8B | -2.4B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | -542.6M | -361.7M | -542.6M | -180.8M |
| Debt Issuance | 0 | 5.5B | 3.6B | 3.7B | 5.8B |
| Debt Repayment | -8.8B | -4.8B | -3.4B | -4.5B | -4.1B |
| Financing Cash Flow | -6.3B | 1.0B | 763.7M | 463.6M | 433.5M |
| Free Cash Flow | 4.4B | 7.9B | 3.4B | 3.7B | 5.6B |
| Net Change in Cash | -291.6M | 2.4B | 3.1B | -2.1B | 757.6M |
Cash Flow Trend
Emcure Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
34.91
Forward P/E
25.93
Price to Book
6.40
Price to Sales
3.43
PEG Ratio
0.70
Profitability Ratios
Profit Margin
9.83%
Operating Margin
15.04%
Return on Equity
14.68%
Return on Assets
8.28%
Financial Health
Current Ratio
1.52
Debt to Equity
33.97
Per Share Data
EPS (TTM)
₹45.86
Book Value per Share
₹250.31
Revenue per Share
₹466.98
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| EMCURE | 303.5B | 34.91 | 6.40 | 14.68% | 9.83% | 33.97 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Dr. Reddy's | 1.1T | 19.40 | 2.94 | 16.10% | 16.36% | 18.03 |
| Lupin | 1.1T | 22.74 | 5.37 | 18.98% | 17.76% | 31.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.





